GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Other Current Payables

Noile-Immune Biotech (TSE:4893) Other Current Payables : 円0.0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Other Current Payables?

Noile-Immune Biotech's Other Current Payables for the quarter that ended in Mar. 2024 was 円0.0 Mil.

Noile-Immune Biotech's quarterly Other Current Payables stayed the same from Sep. 2023 (円0.0 Mil) to Dec. 2023 (円0.0 Mil) but then increased from Dec. 2023 (円0.0 Mil) to Mar. 2024 (円0.0 Mil).


Noile-Immune Biotech Other Current Payables Historical Data

The historical data trend for Noile-Immune Biotech's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Other Current Payables Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Current Payables
- - - -

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Payables Get a 7-Day Free Trial Premium Member Only - - - - -

Noile-Immune Biotech Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Noile-Immune Biotech Other Current Payables Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines